Representation of Luminera Derm in the Sale of its Dermal Business to AbbVie

By Raz Tepper & Sharon Klein-Manbar & Anat Shavit & Ziv Schwartz & Sharona Haim Pour - Abramovich & Yuval Peled & Ben Strauss & Hila Zackay & Ephraim Friedman & Audrey Abensur & Shaul Mizrahi & Moran Friedman | Oct 2020 | Transaction

Representation of Luminera Derm Ltd. and its affiliated companies in a share and asset transaction, pursuant to which Luminera sold its dermal filler portfolio and R&D pipeline to AbbVie Inc. (NYSE: ABBV) unit Allergan Aesthetics, for a consideration of hundreds of millions of dollars.

Luminera Derm is an R&D company as well as a manufacturer of injectable medical devices in the aesthetic medicine field. The company’s portfolio includes a complete line of injectable beauty solution- hyaluronic acid based dermal fillers (Hydryalix and Hydryal), calcium hydroxyapatite based dermal filler (Crystalys) and the unique one of a kind composite matrix dermal filler composed of calcium hydroxyapatite and hyaluronic acid (HArmonyCa).

Press:  see here